Kan N, Ohgaki K, Inamoto T, Kodama H
Cancer Immunol Immunother. 1984;18(3):215-22. doi: 10.1007/BF00205514.
Spleen cells of BALB/c mice that had been inoculated with syngeneic plasmacytoma MOPC 104E were cultured for 11 days in T-cell growth factor (TCGF) and ultrasonicated tumor extract (USE). Cultured lymphocytes (MOPC-CL) possessed three-fold more lytic units than normal spleen cells cultured in TCGF without USE (N-CL). Moreover, the in vivo neutralization assay suggested that MOPC-CL were composed of at least two populations, one possessing tumor-specific and the other nonspecific antitumor activity. When 2 X 10(7) of MOPC-CL were administered IP to mice that had been inoculated IP with 10(5) MOPC 104E cells 5 days previously marginal prolongation of survival was observed. This effect was not augmented by the single injection of a larger number (5 X 10(7] of CL, but was augmented by the repeated daily administration for 4 days (from day 5 to day 8 after the inoculation) of the same total number (5 X 10(7] of CL. In addition, IP injection of the streptococcal preparation OK432 before the transfer of CL significantly enhanced the therapeutic efficacy, and resulted in a cure rate of 20%. The mechanism of this combined effect appears to involve the effect of OK432 on interleukin 2 (IL-2) regulation systems in vivo. Our culture system with TCGF and USE and our therapy system with OK432 and CL allow the clinical application of adoptive immunotherapy for the many types of solid cancers.
用同基因浆细胞瘤MOPC 104E接种的BALB/c小鼠的脾细胞,在T细胞生长因子(TCGF)和超声破碎的肿瘤提取物(USE)中培养11天。培养的淋巴细胞(MOPC-CL)比在不含USE的TCGF中培养的正常脾细胞(N-CL)具有多三倍的溶细胞单位。此外,体内中和试验表明MOPC-CL至少由两个群体组成,一个具有肿瘤特异性,另一个具有非特异性抗肿瘤活性。当给5天前腹腔接种10⁵个MOPC 104E细胞的小鼠腹腔注射2×10⁷个MOPC-CL时,观察到存活时间有边缘性延长。单次注射大量(5×10⁷个)CL并没有增强这种效果,但在接种后第5天至第8天连续4天每天重复注射相同总数(5×10⁷个)的CL则增强了这种效果。此外,在注射CL之前腹腔注射链球菌制剂OK432显著提高了治疗效果,治愈率达到20%。这种联合效应的机制似乎涉及OK432对体内白细胞介素2(IL-2)调节系统的作用。我们用TCGF和USE的培养系统以及用OK432和CL的治疗系统使得过继性免疫疗法能够临床应用于多种实体癌。